

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 12.09.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test	Sample	Group		N	Result	N <sub>rel</sub>
<b>(601) A1 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	>>>	6	Strong positive (3+)	12 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	13	Strong positive (3+)	27 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	25	Strong positive (3+)	51 %
	(999)	another manufacturer	>>>	5	Strong positive (3+)	10 %
Total per sample: n = 49				Success: 100 %		
Total success: 100 %						
<b>(602) A2 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	>>>	6	Negative (0)	12 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	13	Negative (0)	27 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	25	Negative (0)	51 %
	(999)	another manufacturer	>>>	4	Negative (0)	8,2 %
			>	1	Negative (1+)	2,0 %
Total per sample: n = 49				Success: 100 %		
Total success: 100 %						
<b>(603) A3 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest		1	Negative (1+)	2,0 %
			>>>	5	Weak positive (2+)	10 %
	(803)	Dako c-erbB-2 Onkoprotein		1	Negative (1+)	2,0 %
			>>>	11	Weak positive (2+)	22 %
			>	1	Strong positive (3+)	2,0 %
	(804)	Ventana PATHWAY anti-HER-2/neu		3	Negative (1+)	6,1 %
			>>>	22	Weak positive (2+)	45 %
	(999)	another manufacturer		2	Negative (1+)	4,1 %
			>>>	3	Weak positive (2+)	6,1 %
Total per sample: n = 49				Success: 86 %		
Total success: 86 %						
<b>(606) B1 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	>>>	6	Negative (0)	13 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	11	Negative (0)	23 %
			>	2	Negative (1+)	4,2 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	24	Negative (0)	50 %
			>	1	Negative (1+)	2,1 %
	(999)	another manufacturer	>>>	4	Negative (0)	8,3 %
Total per sample: n = 48				Success: 100 %		
Total success: 100 %						
<b>(607) B2 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	>>>	6	Weak positive (2+)	12 %
	(803)	Dako c-erbB-2 Onkoprotein	>>>	11	Weak positive (2+)	22 %
			>	2	Strong positive (3+)	4,1 %
	(804)	Ventana PATHWAY anti-HER-2/neu	>>>	22	Weak positive (2+)	45 %
			>	3	Strong positive (3+)	6,1 %
	(999)	another manufacturer		1	Negative (0)	2,0 %
			>>>	3	Weak positive (2+)	6,1 %
			>	1	Strong positive (3+)	2,0 %
Total per sample: n = 49				Success: 98 %		
Total success: 98 %						
<b>(608) B3 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	±	1	Negative (0)	2,0 %
			±	3	Negative (1+)	6,1 %
			±	2	Weak positive (2+)	4,1 %
	(803)	Dako c-erbB-2 Onkoprotein	±	2	Negative (1+)	4,1 %
			±	10	Weak positive (2+)	20 %
			±	1	Strong positive (3+)	2,0 %
	(804)	Ventana PATHWAY anti-HER-2/neu	±	1	Negative (0)	2,0 %
			±	9	Negative (1+)	18 %
			±	15	Weak positive (2+)	31 %
	(999)	another manufacturer	±	2	Negative (0)	4,1 %
			±	2	Negative (1+)	4,1 %
			±	1	Strong positive (3+)	2,0 %
Total per sample: n = 49				Success (only evaluated results): not assessed		
<b>(611) C1 expression HER-2/neu</b>						
Slide	(802)	Dako HercepTest	±	2	Negative (0)	4,2 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 12.09.2022

Test		N	Result	N <sub>rel</sub>
Sample	Group			
Slide	(802) Dako HercepTest	± 3	Negative (1+)	6,3 %
		± 1	Weak positive (2+)	2,1 %
(803) Dako c-erbB-2 Onkoprotein		± 1	Negative (0)	2,1 %
		± 3	Negative (1+)	6,3 %
		± 9	Weak positive (2+)	19 %
		± 9	Negative (1+)	19 %
(804) Ventana PATHWAY anti-HER-2/neu		± 16	Weak positive (2+)	33 %
		± 1	Negative (0)	2,1 %
(999) another manufacturer		± 3	Negative (1+)	6,3 %
		Total per sample: n = 48 Success (only evaluated results): not assessed		

**(612) C2 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 6	Strong positive (3+)	12 %
		>>> 13	Strong positive (3+)	27 %
		>>> 25	Strong positive (3+)	51 %
		>>> 5	Strong positive (3+)	10 %
Total per sample: n = 49 Success: 100 %				
Total success: 100 %				

**(613) C3 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 6	Negative (0)	12 %
		>>> 2	Negative (0)	4,1 %
(803) Dako c-erbB-2 Onkoprotein		>>> 8	Negative (1+)	16 %
		2	Weak positive (2+)	4,1 %
		1	Strong positive (3+)	2,0 %
		>>> 5	Negative (0)	10 %
(804) Ventana PATHWAY anti-HER-2/neu		>>> 17	Negative (1+)	35 %
		3	Weak positive (2+)	6,1 %
		>>> 4	Negative (0)	8,2 %
(999) another manufacturer		>>> 1	Weak positive (2+)	2,0 %
		Total per sample: n = 49 Success: 86 %		
Total success: 86 %				

**(616) D1 expression HER-2/neu**

Slide	(802) Dako HercepTest	2	Negative (1+)	4,1 %
		>>> 4	Weak positive (2+)	8,2 %
(803) Dako c-erbB-2 Onkoprotein		2	Negative (1+)	4,1 %
		>>> 10	Weak positive (2+)	20 %
		> 1	Strong positive (3+)	2,0 %
(804) Ventana PATHWAY anti-HER-2/neu		3	Negative (1+)	6,1 %
		>>> 22	Weak positive (2+)	45 %
(999) another manufacturer		1	Negative (0)	2,0 %
		1	Negative (1+)	2,0 %
		>>> 2	Weak positive (2+)	4,1 %
Total per sample: n = 49 Success: 82 %				
Total success: 82 %				

**(617) D2 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 5	Negative (0)	10 %
		> 1	Negative (1+)	2,1 %
(803) Dako c-erbB-2 Onkoprotein		>>> 13	Negative (0)	27 %
		>>> 24	Negative (0)	50 %
(804) Ventana PATHWAY anti-HER-2/neu		> 1	Negative (1+)	2,1 %
		>>> 4	Negative (0)	8,3 %
Total per sample: n = 48 Success: 100 %				
Total success: 100 %				

**(618) D3 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 6	Strong positive (3+)	12 %
		>>> 1	Weak positive (2+)	2,0 %
(803) Dako c-erbB-2 Onkoprotein		>>> 12	Strong positive (3+)	24 %
		1	Negative (1+)	2,0 %
(804) Ventana PATHWAY anti-HER-2/neu		>>> 6	Weak positive (2+)	12 %
		>>> 18	Strong positive (3+)	37 %
(999) another manufacturer		>>> 2	Weak positive (2+)	4,1 %
		>>> 3	Strong positive (3+)	6,1 %
Total per sample: n = 49 Success: 98 %				
Total success: 98 %				

**(621) E1 expression HER-2/neu**

Slide	(802) Dako HercepTest	1	Negative (1+)	2,0 %
		>>> 5	Weak positive (2+)	10 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 12.09.2022

Test		N	Result	N <sub>rel</sub>
Sample	Group			
Slide	(803) Dako c-erbB-2 Onkoprotein	2	Negative (1+)	4,1 %
		>>> 11	Weak positive (2+)	22 %
	(804) Ventana PATHWAY anti-HER-2/neu	3	Negative (1+)	6,1 %
		>>> 22	Weak positive (2+)	45 %
	(999) another manufacturer	1	Negative (0)	2,0 %
		2	Negative (1+)	4,1 %
		>>> 2	Weak positive (2+)	4,1 %
Total per sample: n = 49		Success: 82 %		
Total success: 82 %				
<b>(622) E2 expression HER-2/neu</b>				
Slide	(802) Dako HercepTest	>	1 Negative (0)	2,1 %
		>>> 3	Negative (1+)	6,3 %
		1	Weak positive (2+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein	>	1 Negative (0)	2,1 %
		>>> 11	Negative (1+)	23 %
		1	Weak positive (2+)	2,1 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	1 Negative (0)	2,1 %
		>>> 15	Negative (1+)	31 %
		9	Weak positive (2+)	19 %
	(999) another manufacturer	>	2 Negative (0)	4,2 %
		>>> 2	Negative (1+)	4,2 %
		1	Weak positive (2+)	2,1 %
Total per sample: n = 48		Success: 75 %		
Total success: 75 %				
<b>(623) E3 expression HER-2/neu</b>				
Slide	(802) Dako HercepTest	>>> 6	Strong positive (3+)	12 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 13	Strong positive (3+)	27 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 25	Strong positive (3+)	51 %
	(999) another manufacturer	>>> 5	Strong positive (3+)	10 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(651) A1 sample staining</b>				
Slide	(0) not specified	1	0 points	2,0 %
		>	2 3 points	4,1 %
		>>> 46	6 points	94 %
Total per sample: n = 49		Success: 98 %		
Total success: 98 %				
<b>(652) A2 sample staining</b>				
Slide	(0) not specified	>>> 49	6 points	100 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(653) A3 sample staining</b>				
Slide	(0) not specified	1	0 points	2,0 %
		>	5 3 points	10 %
		>>> 43	6 points	88 %
Total per sample: n = 49		Success: 98 %		
Total success: 98 %				
<b>(656) B1 sample staining</b>				
Slide	(0) not specified	>>> 48	6 points	100 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(657) B2 sample staining</b>				
Slide	(0) not specified	1	0 points	2,1 %
		>	4 3 points	8,3 %
		>>> 43	6 points	90 %
Total per sample: n = 48		Success: 98 %		
Total success: 98 %				
<b>(658) B3 sample staining</b>				
Slide	(0) not specified	± 49	6 points	100 %
Total per sample: n = 49		Success (only evaluated results): not assessed		
<b>(661) C1 sample staining</b>				
Slide	(0) not specified	± 49	6 points	100 %
Total per sample: n = 49		Success (only evaluated results): not assessed		
<b>(662) C2 sample staining</b>				
Slide	(0) not specified	>	5 3 points	10 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC2/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 12.09.2022

Test		N	Result	N <sub>rel</sub>
Sample	Group			
Slide	(0) not specified	>>> 44	6 points	90 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(663) C3 sample staining</b>				
Slide	(0) not specified	> 2	3 points	4,1 %
		>>> 47	6 points	96 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(666) D1 sample staining</b>				
Slide	(0) not specified	2	0 points	4,1 %
		> 10	3 points	20 %
		>>> 37	6 points	76 %
Total per sample: n = 49		Success: 96 %		
Total success: 96 %				
<b>(667) D2 sample staining</b>				
Slide	(0) not specified	>>> 48	6 points	100 %
Total per sample: n = 48		Success: 100 %		
Total success: 100 %				
<b>(668) D3 sample staining</b>				
Slide	(0) not specified	>>> 49	6 points	100 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(671) E1 sample staining</b>				
Slide	(0) not specified	1	0 points	2,0 %
		> 9	3 points	18 %
		>>> 39	6 points	80 %
Total per sample: n = 49		Success: 98 %		
Total success: 98 %				
<b>(672) E2 sample staining</b>				
Slide	(0) not specified	1	0 points	2,0 %
		> 1	3 points	2,0 %
		>>> 47	6 points	96 %
Total per sample: n = 49		Success: 98 %		
Total success: 98 %				
<b>(673) E3 sample staining</b>				
Slide	(0) not specified	> 2	3 points	4,1 %
		>>> 1	5 points	2,0 %
		>>> 46	6 points	94 %
Total per sample: n = 49		Success: 100 %		
Total success: 100 %				
<b>(681) IQC</b>				
Slide	(0) not specified	4	0 points	8,2 %
		1	1 point	2,0 %
		> 12	3 points	24 %
		> 1	4 points	2,0 %
		>>> 1	5 points	2,0 %
		>>> 30	6 points	61 %
Total per sample: n = 49		Success: 90 %		
Total success: 90 %				